WS6

Catalog No.S7442 Batch:S744201

Technical Data

Formula	C₂₉H₃₁F₃N₆O₃
Molecular Weight	568.59	CAS No.	1421227-53-3
Solubility (25°C)*	In vitro	DMSO	100 mg/mL (175.87 mM)
		Ethanol	100 mg/mL (175.87 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

WS6 is a β cell proliferation inducer via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway.

Targets

EBP1 ^[1]

IκB kinase ^[1]

In vitro

WS6 induces R7T1 cell proliferation with EC50 of 0.28 μM, and promotes β cell proliferation in rodent and human primary islets. Both Erb3 binding protein-1 and the IκB kinase pathway are confirmed to function in the mechanism of action of WS6. ^[1]

In vivo

In RIP-DTA mouse model of β cell ablation, WS6 (50 mg/kg p.o.) ameliorates diabetes, and induces concomitant increases in β cell proliferation and β cell number. ^[1]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines R7T1 cells Concentrations ~10 μM Incubation Time 4 days Method R7T1 cells are growth-arrested by removal of doxycycline for 2 days and plated into 384-well plates at a density of 3,000 cells/well in growth medium. Β cell proliferation is assessed using CellTiter Glo after 4 days. Fold increase in cell number is calculated by normalizing compound-treated wells to the median of DMSO-treated wells.

Cell Assay:^{^[1]}

Cell lines
R7T1 cells
Concentrations
~10 μM
Incubation Time
4 days
Method
R7T1 cells are growth-arrested by removal of doxycycline for 2 days and plated into 384-well plates at a density of 3,000 cells/well in growth medium. Β cell proliferation is assessed using CellTiter Glo after 4 days. Fold increase in cell number is calculated by normalizing compound-treated wells to the median of DMSO-treated wells.

References

[1] Shen W, et al. J Am Chem Soc. 2013, 135(5), 1669-1672.

Selleck's WS6 has been cited by 4 publications

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML [ Nat Commun, 2024, 15(1):4739]	PubMed: 38834613
Induction of mouse totipotent stem cells by a defined chemical cocktail [ Nature, 2022, 10.1038/s41586-022-04967-9]	PubMed: 35728625
Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia [ Cancers -Basel, 2021, 13-246181]	PubMed: 34944800
Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia [ Cancers (Basel), 2021, 13(24)6181]	PubMed: 34944800

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.